Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform

Impact · against what's priced in

Decoy Therapeutics' partnership with the Gates Foundation and the clear timeline for its lead asset's IND filing provide significant fundamental catalysts. The combination of non-dilutive funding for a scalable manufacturing platform and a concrete path toward clinical trials materially increases the company's valuation profile.

DCOY+0.70

No priced-in read yet